Allarity Therapeutics Exchanges $3 Million of Debt for $3.15 Million of Preferred Stock
Allarity Therapeutics (ALLR) converted $3M debt to Streeterville Capital into $3.15M of preferred stock. The deal, closed Nov. 16, 2026, includes a side letter requiring 33% of future ATM sales proceeds to go to Streeterville. No cash changed hands.
How this was made

The 30-second read
Why it matters
This is a capital-structure event that can affect dilution expectations and cash runway perceptions, especially because the exchange closed with no cash proceeds to the company.
Market read
Financing mechanics (preferred equity issuance and a proceeds sweep tied to ATM sales) are likely to drive near-term trading as investors reassess dilution and funding overhang.
What to watch
Traders should monitor whether the ATM is actually activated and at what pace, since the 33% sweep only matters to the extent proceeds are generated; also watch for any subsequent amendments that change consent revocability or redemption terms.
Background
The article summarizes an 8-K describing a debt-for-preferred-stock exchange and a side letter that conditions future at-the-market (ATM) sales consent.
Ticker impact
Allarity Therapeutics exchanged $3M of debt for $3.15M of preferred stock and secured conditional ATM consent with a 33% weekly proceeds sweep to Streeterville.
Likely downside or volatility as investors price in dilution and constrained cash availability from ATM proceeds.
The filing describes a debt-to-equity conversion with no cash proceeds and a contractual diversion of 33% of weekly ATM proceeds, both of which typically worsen dilution/cash-flow optics for small-cap biotech.
Market effects
Highlights continued reliance on equity-linked financing structures (preferred equity plus ATM) among small-cap biotechs, reinforcing dilution risk as a sector theme.
Limited broader market impact; primarily affects US small-cap biotech sentiment and financing-cost expectations.
Low, as the event is company-specific and tied to US SEC filings and an ATM mechanism.
Counterpoint
The debt-for-equity exchange may reduce near-term creditor pressure and could be viewed as a stabilization step if it prevents more expensive or restrictive refinancing.
Key entities
- issuerAllarity Therapeutics, Inc.
Company that exchanged $3M debt for $3.15M preferred stock and entered conditional consent for future ATM sales.
- counterpartyStreeterville Capital
Creditor and counterparty receiving preferred-stock redemption/note repayment and receiving 33% of weekly net ATM proceeds under the side letter.